ClinicalTrials.gg
CompletedNCT05163561Updated Oct 23, 2023

Evaluation of Safety and Immunogenicity of Inactivated Adjuvanted Polio Vaccine in Comparison With Licensed Inactivated Poliovirus Vaccine

A Phase 3 interventional study of SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot A and SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot B in Poliomyelitis, sponsored by Serum Institute of India Pvt. Ltd.. Completed at 1 site in Bangladesh. Open to participants aged 6 Weeks to 8 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-23.

Sponsored by Serum Institute of India Pvt. Ltd. · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,072
Allocation
Randomized
Ages
6 Weeks to 8 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 23 studies in Poliomyelitis with a site in Bangladesh — 3 open to participants now, 3 under way, 1 of them phase 3. Poliomyelitis · Bangladesh.

Enrollment
11th of 22
1,072 · median 1,015
Started
2022
with 1 other
Phase 3
7 of 23
1 open now
Registered
15th of 23
by date
Lead sponsor
3 of 23
Serum Institute of India Pvt. Ltd.

Among the 23 studies in Poliomyelitis with a site in Bangladesh, this one is the 11th largest by enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2022, is one of 7 in phase 3, and was the 15th registered.

Poliomyelitis

275 studies on the registry are indexed under Poliomyelitis; 19 are open to participants now.

Browse Poliomyelitis studies →

Open to participants now

3 of the 23 studies in Poliomyelitis with a site in Bangladesh are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Bangladesh have not opened yet or have stopped. Only those recruiting at a site in Bangladesh →

Who these studies take

Of the 11 Poliomyelitis studies recruiting now, none (0%) set no upper age limit and 11 (100%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 6 Weeks to 8 Weeks · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Poliomyelitis with a site in Bangladesh, or all of them as a file.
02

Study summary

This Phase III study has been designed to compare the SII Inactivated Salk Polio Vaccine (Adsorbed) with Sii licensed IPV by testing the vaccine in infants (three doses administered 4 weeks apart, starting at 6-8 weeks of age) in order to demonstrate the non-inferiority in the induction of specific poliovirus neutralizing antibody (PVNA) to poliovirus type 1, type 2 and type 3 by these vaccines. The study will also evaluate lot-to-lot consistency in the manufacture of SII Inactivated Salk Polio Vaccine (Adsorbed) by demonstrating equivalence in the induction of PVNA across three production lots.

Read the detailed description

The study is designed as a double-blind, randomized, active-controlled Phase III study with four groups of infants (n=268 per group) receiving either SII Inactivated Salk Polio Vaccine (Adsorbed) from the three lots or Sii licensed IPV.

Participants will be screened for eligibility with their parental consent and will be selected for the study according to inclusion and exclusion criteria. A total of 1072 participants will be enrolled.

Following vaccination, enrolled participants will remain in the clinic for at least 30 minutes for observation. During this time, they will be closely monitored for any immediate adverse events. Safety will be evaluated by active surveillance for solicited adverse events over the 4-day period after each vaccination in all participants. In addition, surveillance for unsolicited AEs and SAEs will be carried out over the period from first vaccination and 28 days after the third vaccination in all participants.

The immunogenicity will be assessed by measuring the PVNA to poliovirus type 1, type 2 and type 3 using a standardized microneutralization test in the sera samples of the participants.

03

Conditions studied

  • Poliomyelitis

Browse trials for

04

Who can participate

Ages eligible
6 Weeks to 8 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy infants as established by medical history and clinical examination before entering the study
  2. Age: 6-8 weeks at the time of enrolment
  3. Parental ability and willingness to provide
  4. Parent who intends to reside in the area with the infant during the study period

Exclusion criteria

Exclusion Criteria:

  1. Presence of fever on the day of enrolment [Temporary exclusion criteria].
  2. Acute disease at the time of enrolment [Temporary exclusion criteria].
  3. Prior receipt or intent to receive OPV/IPV/IPV containing vaccines during the study period.
  4. OPV vaccination or known exposure to poliovirus (wild or vaccine derived) in household (living together) within 3-months prior to inclusion or planned during the study.
  5. Presence of significant malnutrition (weight-for-height z-score \< -3SD median)
  6. Known or suspected impairment of immunological function based on medical history and physical examination.
  7. Presence of any systemic disorder (cardiovascular, pulmonary, hepatic, renal, gastrointestinal, hematological, endocrine, immunological, dermatological, neurological, cancer, or disease) as determined by medical history and / or physical examination which would compromise the participant's health or is likely to result in nonconformance to the protocol.
  8. A known sensitivity or allergy to any components of the Product.
  9. Receipt of immunoglobulin therapy and / or blood products since birth or planned administration during the study period
  10. Planned concurrent participation in another clinical study at any point throughout the entire study period
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,072 participants (actual)

Study arms

  • Experimental
    SII Inactivated Salk Polio Vaccine (Adsorbed) Lot A

    SII Inactivated Salk Polio Vaccine (Adsorbed) Lot A

    Biological: SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot A

  • Experimental
    SII Inactivated Salk Polio Vaccine (Adsorbed) Lot B

    SII Inactivated Salk Polio Vaccine (Adsorbed) Lot B

    Biological: SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot B

  • Experimental
    SII Inactivated Salk Polio Vaccine (Adsorbed) Lot C

    SII Inactivated Salk Polio Vaccine (Adsorbed) Lot C

    Biological: SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot C

  • Active comparator
    Sii Licensed IPV

    Sii Licensed IPV

    Biological: Sii Licensed IPV

Interventions

  • BiologicalSII Inactivated Salk Polio Vaccine (Adsorbed) - Lot A

    SII Inactivated Salk Polio Vaccine (Adsorbed) produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). It is a highly purified, adjuvanted reduced antigen content of inactivated poliovirus vaccine.

  • BiologicalSII Inactivated Salk Polio Vaccine (Adsorbed) - Lot B

    SII Inactivated Salk Polio Vaccine (Adsorbed) produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). It is a highly purified, adjuvanted reduced antigen content of inactivated poliovirus vaccine.

  • BiologicalSII Inactivated Salk Polio Vaccine (Adsorbed) - Lot C

    SII Inactivated Salk Polio Vaccine (Adsorbed) produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). It is a highly purified, adjuvanted reduced antigen content of inactivated poliovirus vaccine.

  • BiologicalSii Licensed IPV

    Poliomyelitis Vaccine (Inactivated), produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). Poliomyelitis Vaccine (Inactivated) is a highly purified, inactivated poliovirus vaccine.

06

What researchers measure

Primary outcomes

  1. Percentage of participants with type-specific seroconversion

    Percentage of participants with type-specific seroconversion\* on Day 28 after the third vaccination for SII Inactivated Salk Polio Vaccine (Adsorbed) and Sii Licensed IPV

    Time frame: Day 28 after third vaccination

Secondary outcomes

  1. Geometric Mean Titers

    Type-specific geometric mean titers on day 28 after the third vaccination of three cGMP lots of SII Inactivated Salk Polio Vaccine (Adsorbed) and Sii Licensed IPV.

    Time frame: Day 28 after third vaccination

  2. Reverse cumulative distribution curves of antibody titers

    Type-specific reverse cumulative distribution curves of antibody titers on pre-vaccination and 28 days after third vaccination of three cGMP lots of SII Inactivated Salk Polio Vaccine (Adsorbed) and Sii Licensed IPV.

    Time frame: pre-vaccination and 28 days after third vaccination

  3. Percentage of participants with type-specific seroprotection

    Percentage of participants with type-specific seroprotection (titers ≥ 8) on Day 28 after the third vaccination of three cGMP lots of SII Inactivated Salk Polio Vaccine (Adsorbed) and Sii Licensed IPV.

    Time frame: Day 28 after the third vaccination

  4. Percentage of participants with type-specific post-vaccination titers ≥ 4-fold above the estimated titer of maternal antibody

    Percentage of participants with type-specific post-vaccination titers ≥ 4-fold above the estimated titer of maternal antibody on day 28 after the third vaccination of three cGMP lots of SII Inactivated Salk Polio Vaccine (Adsorbed) and Sii Licensed IPV.

    Time frame: Day 28 after the third vaccination

07

Study locations

1 site
  • International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B)
    Dhaka, 128, Bangladesh
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Apr 2023, 15 months.

Of 36 industry-sponsored phase 3 interventional studies under Poliomyelitis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 21. This study's 15 months is close to that.

Counting every sponsor, half of 45 studies reached it within 12 months; a quarter within 7 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2021
First posted
Dec 20, 2021
StartActual
Jan 9, 2022
Primary completionActual
Apr 29, 2023
CompletionActual
Apr 29, 2023
Last update
Oct 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05163561
Responsible party
Sponsor
First posted
Dec 20, 2021
Start date
Jan 9, 2022
Primary completion
Apr 29, 2023
Completion
Apr 29, 2023
Last update
Oct 23, 2023

Study contacts

K Zaman, MD
principal investigator · International Centre for Diarrhoeal Disease Research, Bangladesh

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion